We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
323 result(s) found, displaying 131 to 140
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Budesonide / glycopyrronium / formoterol
-
Prescription medicine decision summaryTGA Decision: Saphnelo (anifrolumab) is approved to treat adult patients with active systemic lupus erythematosus (SLE).
-
Australian public assessment report (AusPar)Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
proteinuric chronic kidney disease. -
-
Designation or determinationProvisional determination
-
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Australian public assessment report (AusPar)New AusPAR for EVUSHELD (tixagevimab and cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years older
-
Prescription medicine decision summaryTGA decision: Evusheld (tixagevimab/cilgavimab) is approved for the treatment of pre-exposure prophylaxis of COVID-19.
-
Prescription medicine registrationActive ingredients: cilgavimab; tixagevimab.